Reference : Le medicament du mois. L'aliskiren (Rasilez), inhibiteur direct de la renine.
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Urology & nephrology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/4176
Le medicament du mois. L'aliskiren (Rasilez), inhibiteur direct de la renine.
French
[fr] Aliskiren (Rasilez), direct renin inhibitor
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Pierard, Luc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
Krzesinski, Jean-Marie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Néphrologie >]
2008
Revue Médicale de Liège
63
9
564-9
Yes (verified by ORBi)
National
0370-629X
Belgium
[en] Aliskiren ; Renin ; angiotensin ; aldosterone system ; Renin inhibitor ; Hypertension
[fr] Heart failure ; Nephropathy
[en] Aliskiren (Rasilez) is the first oral renin inhibitor. Its present indication is essential hypertension, as monotherapy or in combination with other antihypertensive agents (diuretic, calcium antagonist, ...). It may also be associated with an angiotensin converting enzyme inhibitor (or an AT1 angiotensin receptor antagonist) in order to benefit of a dual blockade of the renin-angiotensin-aldosterone system. The usual daily dose is 150 mg, to be increased up to 300 mg if necessary. New clinical trials are ongoing to validate this novel therapeutic approach in other indications such as congestive heart failure and diabetic nephropathy.
Professionals ; Students
http://hdl.handle.net/2268/4176
http://www.rmlg.ulg.ac.be/index.php?page=resume?num_id=1790

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
200809_09.pdfNo commentaryPublisher postprint511.04 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.